

(b) amino acids 2 to 331 of SEQ ID NO:2 or the complete amino acid sequence excepting the N-terminal methionine encoded by the cDNA clone contained in ATCC Deposit No. 97343;

(c) amino acids 24 to 331 of SEQ ID NO:2;

(d) amino acids 27 to 331 of SEQ ID NO:2; and

(e) the amino acid sequence of the mature form of Neuronal Attachment Factor-1 (NAF-1) encoded by the cDNA clone contained in ATCC Deposit No. 97343;

wherein said polypeptide promotes neuronal cell adhesion or axonal neurite extension.

28. (Once amended) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) amino acids 1 to 331 of SEQ ID NO:2;

(b) the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97343;

(c) amino acids 2 to 331 of SEQ ID NO:2,

(d) the complete amino acid sequence excepting the N-terminal methionine encoded by the cDNA clone contained in ATCC Deposit No. 97343;

(e) amino acids 24 to 331 of SEQ ID NO:2;

(f) amino acids 27 to 331 of SEQ ID NO:2; and

(g) the amino acid sequence of the mature form of NAF-1 encoded by the cDNA clone contained in ATCC Deposit No. 97343.

29. (Once amended) The isolated polypeptide of claim 28 wherein said amino acid sequence is (a).

30. (Once amended) The isolated polypeptide of claim 28 wherein said amino acid sequence is (b).

31. (Once amended) The isolated polypeptide of claim 28 wherein said amino acid sequence is (c).

32. (Once amended) The isolated polypeptide of claim 28 wherein said amino acid sequence is (d).

33. (Once amended) The isolated polypeptide of claim 28 wherein said amino acid sequence is (e).

34. (Once amended) The isolated polypeptide of claim 28 wherein said amino acid sequence is (f).

35. (Once amended) The isolated polypeptide of claim 28 wherein said amino acid sequence is (g).

36. (Once amended) An epitope-bearing portion of the NAF-1 polypeptide consisting of at least 9 contiguous amino acids of SEQ ID NO:2.

37. (Once amended) The epitope-bearing portion of claim 36, which consists of at least 15 contiguous amino acids of SEQ ID NO:2.

38. (Once amended) The epitope-bearing portion of claim 36, wherein said portion consists of at least amino acids 75 to 100 of SEQ ID NO:2.

39. (Once amended) The epitope-bearing portion of claim 36, wherein said portion consists of at least amino acids 168 to 180 of SEQ ID NO:2.

40. (Once amended) The epitope-bearing portion of claim 36, wherein said portion consists of at least amino acids 204 to 226 of SEQ ID NO:2.

41. (Once amended) The epitope-bearing portion of claim 36, wherein said portion consists of at least amino acids 258 to 281 of SEQ ID NO:2.

42. (Once amended) The epitope-bearing portion of claim 36, wherein said portion consists of at least amino acids 291 to 327 of SEQ ID NO:2.

C<sup>2</sup>  
cont.  
43. (Once amended) An isolated polypeptide consisting of at least 10 contiguous amino acids of SEQ ID NO:2.

44. (Once amended) The isolated polypeptide of claim 43, which has at least one activity selected from the group consisting of:

- (a) promotes axonal neurite extension;
- (b) promotes neural cell adhesion; or
- (c) binds to an antibody specific to the polypeptide of SEQ ID NO:2.

C<sup>3</sup>  
48. (Once amended) The isolated polypeptide of claim 43, which consists of at least 30 contiguous amino acids of SEQ ID NO:2.

49. (Once amended) The isolated polypeptide of claim 43, which consists of at least 50 contiguous amino acids of SEQ ID NO:2.

58. (Once amended) A composition comprising the polypeptide of claim 21 and a carrier.

C<sup>4</sup>  
59. (Once amended) A composition comprising the polypeptide of claim 36 and a carrier.

60. (Once amended) A composition comprising the polypeptide of claim 43 and a carrier.